Observational studyBMC cardiovascular disorders2025
Determinants of polypharmacy among ambulatory cardiovascular disease patients in Iluababora and Buno Bedele Zones, Ethiopia: prospective observational study.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-Institutional Drug Use Patterns in Hospitalized Older Patients: Retrospective Cross-Sectional Study.JMIR medical informatics · 2026Article
- Reno-Metabolic Multimorbidity and Psychiatric Comorbidity: Development of a Renal-Psychiatric/Psychosomatic Burden Score in a Real-World Cohort.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease is still the largest cause of disease in the world. Polypharmacy among cardiovascular disease patients has increased as the population ages and multimorbidity rates grow. This has a negative impact on one’s health and may result in drug interactions. Despite, the potential harm that polypharmacy might bring, little has been done to investigate the prevalence of polypharmacy and its determinants among cardiovascular disease patients, particularly in Ethiopia.
objectiveTo determine magnitude of polypharmacy and its determinants among ambulatory cardiovascular disease patients at public hospitals in Iluababora and Buno Bedele Zones, Southwest Oromia, Ethiopia. METHOD AND
participantsA prospective observational study was conducted from November 1, 2022 to August 30, 2023, at public hospitals in Iluababora and Buno Bedelle Zones. Sample size was 1169 cardiovascular disease patients and consecutive sampling technique was used for recruiting these study participants. The Data was analyzed using statistical software package version 25.0. Bivariable and multivariable logistic regressions were used to identify the determinants of polypharmacy among cardiovascular disease patients and statistical significance was considered at a p-value < 0.05.
resultsThe prevalence of polypharmacy was 31.8% in cardiovascular patients while cardiovascular disease specific polypharmacy was 9.6%. The mean age was 60.52 years ± 14.11.The determinants of polypharmacy among Cardiovascular disease were those who had a history of chewing khat [AOR = 4.08, 95%CI= (1.67–9.95)], age greater than 64 years old [AOR = 4.74, 95%CI= (2.19–10.27)] and those who had a history of cigarette smoking [AOR = 2.86, 95%CI= (1.33–6.15)].
conclusionPolypharmacy was common among ambulatory cardiovascular disease patients in the study area. Chewing khat, being above the age of 64years, and smoking cigarettes were associated factors for polypharmacy among cardiovascular disease patients. Hence, to overcome these problems, clinical pharmacists, physicians, and other health professionals have to work in collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.